Related by context. All words. (Click for frequent words.) 75 fidaxomicin Phase 71 Phase Ib study 70 phase IIb clinical 70 ongoing Phase 1b 70 Phase 1a clinical 70 phase IIa clinical 69 Phase IIb III 68 ORAL Sync 68 SUCCEED trial 68 Phase Ib II 67 phase Ib clinical 67 multicenter Phase II 67 BRIM3 67 trastuzumab DM1 T DM1 67 pivotal bioequivalence 67 phase IIb 67 Phase IIIb clinical 66 ENDEAVOR III 66 TG MV 66 Phase IIB clinical 66 phase IIb III 66 phase IIa 66 Phase Ib clinical 66 Corlux 66 Phase #b/#a clinical 65 ToGA 65 Phase 1b clinical 65 sNDA submission 65 tolevamer 65 Cloretazine ® 65 preclinical efficacy 65 EmbraceAC 65 alvespimycin 65 AVADO 65 dose escalation clinical 65 Amoxicillin PULSYS Phase III 65 trastuzumab emtansine T DM1 65 Phase III VISTA 65 DASISION 64 rALLy trial 64 ENDEAVOR IV 64 ADVANCE PD 64 Phase 2a clinical 64 randomized controlled Phase 64 Phase III ADT 64 viral kinetic 64 phase III ACCLAIM 64 trastuzumab DM1 64 IMA# 64 randomized controlled multicenter 64 phase IIb study 64 dose escalation Phase 64 CA9 SCAN 64 AVERROES 64 candidate CRLX# 64 CUSTOM III 64 SPIRIT IV 64 unblind 64 huC# DM4 64 Phase IIb clinical trials 64 OvaRex ® MAb 64 PFO migraine 64 Phase 2a trial 64 HCV RESPOND 2 63 SAR# [004] 63 pharmacokinetic PK study 63 UPLYSO 63 Azedra 63 MIVI III 63 PROSTVAC TM 63 phase 2a 63 PERSEUS 63 Pivotal Phase III 63 phase IIb trial 63 oral ridaforolimus 63 PRIMO CABG 63 BETAS 63 Phase IIa clinical 63 Phase 2b kidney transplant 63 including eniluracil ADH 63 assessing T DM1 63 GLP toxicology studies 63 Phase III clinical 63 Phase III AFFIRM 63 preclinical pharmacology 63 investigational pan BCR 63 Phase IIa trial 63 fosbretabulin 63 randomized Phase III 63 GRNVAC1 63 Phase Ib IIa 63 Phase IIb clinical 62 Ereska 62 Phase #b/#a 62 NADiA ProsVue 62 ruxolitinib 62 EDEMA3 62 elotuzumab 62 preclinical pharmacokinetic 62 Ophena 62 Phase 1b trial 62 phase IIIb 62 Phase 2b clinical 62 confirmatory clinical 62 JAK inhibitor 62 multicenter randomized controlled 62 Phase III randomized controlled 62 Cloretazine R 62 Prostate AdenoCarcinoma Treatment 62 Phase Ia 62 randomized Phase IIb 62 adecatumumab 62 intravenous acetaminophen 62 Spiegelmer ® 62 miRview ™ mets 62 BR.# 62 SPIRIT FIRST 62 riociguat 62 Genasense ® oblimersen 62 ENDEAVOR IV clinical 62 ExTRACT TIMI 62 ocular formulation 62 Ophena TM 62 midstage trials 62 VESTASYNC 62 crizotinib PF # 62 placebo controlled Phase III 62 Vascular Wrap TM 62 PROVENGE sipuleucel T 62 teriflunomide 62 clevidipine 62 PHX# 62 HCV SPRINT 62 MAGE A3 ASCI 62 MelaFind pivotal 62 midstage studies 62 Proellex TM 62 PDX pralatrexate 62 Solazed 62 CAMMS# 62 Phase #/#a 62 indibulin 62 NP2 Enkephalin 62 ELACYT 62 cediranib 61 hepatitis B vaccine Heplisav 61 PARTNER Trial 61 Phase IIB 61 Androxal TM 61 EXPLORE Xa 61 acyclovir Lauriad R 61 Phase 2b study 61 OvaRex R 61 multicenter Phase III 61 GetGoal Phase III 61 RE LY ® 61 multicenter clinical 61 phase Ib 61 IND submission 61 ASSERT trial 61 RECORD1 61 virus HCV protease inhibitor 61 PROTECT AF 61 ATPace TM 61 Maximum Tolerated Dose MTD 61 CCX# 61 radezolid 61 IMPACT DCM 61 HORIZONS AMI 61 PRECISE trial 61 OncoVEX 61 TQT studies 61 BRIM2 61 Matrix Phase 2b 61 PSMA ADC 61 TBC# 61 Phase 2a clinical trials 61 ONCONASE R 61 initiate Phase 1b 61 neratinib 61 Cervista HPV HR 61 EGS# 61 MEND CABG 61 elacytarabine 61 Onconase 61 FOLOTYN ® 61 Zybrestat 61 dose cohort 61 PEARL SC 61 bortezomib Velcade 61 Amrubicin 61 PANVAC VF 61 cetuximab Erbitux 61 HGS ETR2 61 placebo controlled clinical 61 deforolimus 61 GAMMAGARD 61 AEG# 61 CHAMPION PCI 60 Panzem NCD 60 oral deforolimus 60 EDEMA4 60 VNP#M 60 Phase IIIb 60 multicenter phase 60 Novolimus 60 abstracts summarizing 60 APEX PD 60 mertansine 60 NSABP B 60 evaluating tivozanib 60 Augment Injectable 60 Phase Ib 60 phase III isavuconazole 60 trial evaluating PRX# 60 CARE HF 60 metaglidasen 60 NO# [002] 60 blood serum biomarkers 60 BARI 2D 60 VersaFilm 60 Solorel TM 60 Phase III ALLEGRO 60 Phase III confirmatory 60 PS# DARA 60 prospective multicenter 60 MOZOBIL 60 Azedra TM 60 bicifadine 60 ENDEAVOR II 60 PMA submission 60 galiximab 60 Phase III pivotal 60 adipiplon 60 Phase III psoriasis 60 enzastaurin 60 Aurexis 60 TLK# 60 radiation sensitizer 60 compound INCB# 60 pivotal Phase III 60 bardoxolone 60 BRAF inhibitor 60 midstage clinical 60 multicenter randomized placebo controlled 60 GSK# [002] 60 Phase lll 60 Aflibercept 60 EOquin TM 60 miRview ™ squamous 60 liposomal formulation 60 Zenvia Phase III 60 CBLC# 60 Phase III placebo controlled 60 CRLX# 60 candidate XP# 60 rALLy clinical trial 60 RE LY trial 60 reslizumab 60 Dyloject TM 60 TAXUS IV 60 Phase 2b monotherapy 60 randomized multicenter trial 60 bioequivalency 60 hematological tumors 60 PTK# 60 AMPAKINE CX# 60 Onalta ™ 60 RSD# oral 60 ancrod 60 anticancer compound 60 CLORETAZINE TM VNP#M 60 placebo controlled Phase 60 PrevOnco 60 HCV NS5B polymerase 60 Pimavanserin 60 registrational Phase 60 CEQ# 60 Sibutramine Cardiovascular Outcomes 60 Initiates Phase II 60 BLA submission 60 drug eluting coronary stent 60 LymphoStat B TM 60 OncoVex 60 VITAL Trial 60 Trofex 60 cannabinor 60 Tarceva TM 60 BLOOM DM 60 pharmacokinetic PK 59 Afatinib 59 telomerase inhibitor drug 59 Phase III Pivotal 59 IL# PE#QQR 59 rALLy 59 TOLAMBA 59 lorvotuzumab mertansine 59 REG1 59 NEUGENE R 59 lintuzumab SGN 59 LUX Lung 59 GEM OS2 59 Edwards SAPIEN valve 59 RGB # 59 APF# Phase 59 ganetespib 59 TASKi2 59 Tolamba 59 budesonide foam 59 unblinding 59 PEG SN# 59 CHAMPION PLATFORM 59 recurrent malignant glioma 59 initiated Phase 1b 59 ABSORB trial 59 torezolid phosphate 59 Azedra ™ 59 BrachySil 59 iii GTx 59 Phase IIb trials 59 recurrent herpes labialis 59 BCIRG 59 ABCSG 59 LE SN# 59 brentuximab vedotin SGN 59 ospemifene 59 clinical pharmacology studies 59 Phase 1b clinical trials 59 ALSYMPCA 59 Phase IIIb study 59 Safinamide 59 SYMMETRY trial 59 randomized Phase 2b 59 adecatumumab MT# 59 systemically administered 59 PRT# 59 Genasense ® 59 bazedoxifene conjugated estrogens 59 investigational humanized monoclonal antibody 59 oral taxane 59 Anturol TM 59 double blinded randomized 59 ralfinamide 59 CCR5 inhibitor 59 Phase IIb trial 59 EndoTAG TM 59 OvaRex 59 Achieves Primary Endpoint 59 BLA filing 59 pediatric pontine glioma 59 LUMINATE 59 NSABP C 59 Phase 2b trial 59 budesonide MMX Phase III 59 GALNS 59 BrachySil TM 59 #th Annual Interscience 59 SinuNase ™ 59 registrational 59 Vaxfectin TM 59 ABSORB clinical 59 Aplidin 59 SABCS 59 Hedgehog antagonist 59 e2 Collector 59 CLIRS trial 59 hoFH 59 Nexavar sorafenib 59 Dacogen decitabine 59 Tocosol Paclitaxel 59 CLARITY study 59 ZOLINZA 59 confirmatory Phase III 59 Telatinib 59 NEVO RES 59 OMP #M# 59 ADAGIO study 59 TAXUS ATLAS 59 generation purine nucleoside 59 buccal spray 59 ENRICH trial 59 ImmuKnow R 59 REMINYL ® 59 Aganocide 59 Tesetaxel 59 EVEREST II 59 Thorough QT 59 Targretin capsules 59 Val HeFT 59 Tarvacin TM 59 Civacir 59 YONDELIS 59 interferon gamma 1b 59 VIR# 59 nonclinical studies 59 Phase IIIB IV 59 Soliris eculizumab 59 investigational antiplatelet agent 59 randomized blinded 59 Tykerb lapatinib 59 Randomized Phase 59 initiate Phase IIb 59 PreCISe 59 Dalbavancin 59 Solorel 59 huN# DM1 59 Temsirolimus 59 OHR/AVR# 59 Oglemilast 59 Panzem R NCD 59 H#N# VLP vaccine 59 candidate AQ4N 59 Inc. NASDAQ HEPH 59 omacetaxine mepesuccinate 58 Stimuvax R 58 tramiprosate Alzhemed TM 58 SPARLON 58 Phase IIA 58 budesonide MMX 58 Combination REOLYSIN R 58 PRECiSE 58 Vicinium TM 58 Viramidine 58 TriGrid 58 COMFORT II 58 Vectibix panitumumab 58 retapamulin 58 Omnitarg 58 ticagrelor Brilinta 58 confirmatory Phase 3 58 Deforolimus 58 pharmacokinetic pharmacodynamic 58 initiated Phase Ib 58 NVA# 58 Allovectin 7 58 investigational HCV polymerase 58 Kamada AAT 58 Orathecin 58 ALN TTR# 58 ENMD # 58 pharmacodynamic effects 58 EDEMA3 trial 58 severe hypercholesterolemia 58 Nasdaq RDEA 58 MGd 58 LightTouch 58 INS# [001] 58 Zemiva TM 58 mSEPT9 58 vidofludimus 58 forodesine 58 DXL# 58 PSN# [002] 58 RIO Lipids 58 multicentre randomized 58 Solazed TM 58 ZoMaxx 58 Tovaxin Phase IIb 58 ESBA# 58 pharmacokinetics PK 58 Multikine ® 58 SinuNase TM 58 Angiocept 58 Sigma Tau SpA 58 lumiliximab 58 amrubicin 58 CALGB # [002] 58 thorough QT 58 NASDAQ CXSP announced 58 Cinquil 58 TACI Ig 58 nitric oxide donating prostaglandin 58 metastatic HRPC 58 eTag assays 58 Aurora kinase inhibitor 58 Nasdaq ONXX today 58 QNEXA ® 58 OncoVEX GM CSF 58 lorcaserin Phase 58 DEB# 58 AVOREN 58 CURRENT OASIS 7 58 GRN# 58 Fodosine 58 dextofisopam 58 HGS# 58 CCR5 antagonist 58 bronchial lavage 58 IIa trial 58 PLK1 SNALP 58 investigational hepatitis C 58 Initiated Phase 58 treatment naïve genotype 58 Enzastaurin 58 Phase III ThermoDox 58 LibiGel testosterone gel 58 Lauren Silvernail 58 ATIR 58 oral prodrug 58 Phase #b/#a trial 58 investigational protease inhibitor 58 Aethlon Hemopurifier R 58 multicenter placebo controlled 58 #I TM# 58 T Pred 58 NEO3 58 doxorubicin Transdrug ® 58 dosing cohorts 58 IIa trials 58 ROCKET AF 58 solanezumab 58 histone deacetylase HDAC inhibitor 58 PORxin TM platforms 58 ZK EPO 58 PI3K/Akt pathway inhibitor 58 preclinically 58 Initiate Phase 58 Atu# 58 Mipomersen 58 Plicera 58 PREVENT IV 58 NASDAQ CYTK announced 58 Pyridorin 58 sulodexide 58 aflibercept 58 Sym# 58 Phase 2a 58 Kahalalide F 58 Vidaza R 58 Genasense R oblimersen 58 midstage clinical trials 58 Phase 2b 58 acyclovir Lauriad ® 58 Phase III HEAT 58 phase III SIMPADICO 58 modified REGENESIS Phase IIb 58 multicenter Phase 58 subcutaneous PRO 58 Phase III Clinical Trial 58 Xelox 58 Phase III 58 ponatinib 58 Society CTOS 58 TransVax tm 58 non nucleoside inhibitor 58 ANCHOR trial 58 perifosine KRX 58 RIGScan CR 58 unblinded 58 Dacogen injection 58 Rhucin R 58 PDE4 inhibitor 58 ThermoDox ® clinical 58 SEPET TM 58 multicenter multinational 58 Phase III Clinical Trials 58 PROSTASCINT R 58 bosutinib 58 Phase Ib IIa clinical 58 evaluating REVLIMID 58 immunotherapeutic agent 58 pharmacokinetic studies 58 PRIMO CABG2 58 Phase 2b clinical trials 58 Oncotype DX colon cancer 58 identifier NCT# 58 nucleotide analogue 58 BNC# 58 ritonavir boosted danoprevir 58 TEMSO 58 Exherin TM 58 bevirimat Study 58 orally inhaled migraine 58 CINQUIL 58 hyaluronidase enzyme 58 initiate Phase 2b 58 MEK inhibitor RDEA# 58 Allovectin 7 r 58 clinicaltrials 58 multicenter randomized clinical 58 denosumab oncology 58 TransVax TM 58 CONBRIZA 58 candidates Dyloject TM 58 leading oral taxane 57 vascular disrupting agent 57 Phase IIa trials 57 QuadraSphere 57 genotypic resistance 57 treatment naive genotype 57 Cleviprex TM clevidipine 57 BEMA TM Fentanyl 57 Gattex 57 ORENCIA ® 57 ACAPODENE 57 Inc. Nasdaq CPRX 57 MKC# MT 57 GVAX ® 57 novel VDA molecule 57 zanolimumab 57 Phase IIb 57 Cand5 57 intradermal injections 57 IND CTA 57 Valtropin 57 DPX Survivac 57 ACUITY trial 57 ganaxolone 57 Allovectin 7 ® 57 Completes Patient Enrollment 57 Alocrest 57 ILUVIEN ® 57 docetaxel Taxotere ® 57 Phase IIb kidney transplant 57 sorafenib Nexavar 57 solithromycin 57 preclinical toxicology 57 SUTENT ® 57 vemurafenib 57 Nordic ACTI 57 Genz # 57 biostatistical analysis 57 Factor VIIa 57 vosaroxin 57 ALN VSP Phase 57 G#DT 57 lomitapide 57 Septin9 57 optimal dosing 57 TOCOSOL Camptothecin 57 CLIRS 57 EXPAREL TM 57 Vascular Wrap 57 Advanced Neuroendocrine Tumors 57 generation antisense 57 Zensana TM 57 multicenter clinical trials 57 Urocidin 57 Xanafide 57 Nasdaq MAPP 57 QTinno TM 57 incyclinide 57 everolimus eluting stent 57 HuMax EGFr 57 CTRC AACR San Antonio 57 personalized dendritic 57 epoetin alpha 57 nucleotide analog 57 AERx iDMS 57 ALTROPANE 57 HepaSphere 57 ENTEREG ® 57 teduglutide 57 Meta analyzes 57 Alzhemed TM 57 Neuvenge 57 selective androgen receptor modulator 57 midstage clinical trial 57 BRILINTA 57 AP# [003] 57 receptor tyrosine kinase inhibitor 57 siRNAs targeting 57 Phase #/#a trial 57 balsalazide tablet 57 relapsing remitting MS RRMS 57 FlutiformTM 57 Phase 1b dose escalation 57 miRview meso 57 Asentar 57 PCI ExTRACT TIMI 57 Zenvia ™ 57 Fast Tracked Phase 57 relapsed MCL 57 NEUGENE 57 multicenter randomized Phase 57 CD# CEA 57 phosphatidylserine PS targeting 57 prucalopride 57 seliciclib CYC# 57 BiTE R 57 Elagolix 57 Kynapid 57 Clinical Antipsychotic Trials 57 tubulin inhibitor 57 pan HDAC inhibitor 57 eliglustat tartrate 57 SCIB1 57 landmark ATHENA 57 mitogen activated ERK kinase 57 HDL Selective Delipidation 57 PROactive study 57 kinase profiling 57 CLL8 57 PROVENGE ® 57 generation antisense inhibitor 57 candidate deforolimus 57 SPP# Rasilez 57 EMPHASIS HF trial 57 recombinant PSMA vaccine 57 AeroLEF TM 57 Heplisav 57 CRMD# 57 hypoxia activated prodrug 57 ApoB SNALP 57 generation NNRTI 57 eniluracil 57 ostarine 57 ZACTIMA 57 Annamycin 57 Phase 1b 57 registrational clinical 57 blinded randomized 57 randomized multicenter Phase III 57 HCV protease inhibitor 57 farletuzumab 57 Nasdaq OPTR 57 ARIKACE ™ 57 IIb clinical trial 57 inhaled AAT 57 retaspimycin 57 pharmacodynamic properties 57 CTAP# Capsules 57 BOLDER II 57 CYT# potent vascular disrupting 57 PREGNANT Study 57 THALOMID 57 DermTech International 57 subcutaneous formulation 57 dose escalation trial 57 NASDAQ CLDX 57 maximally tolerated dose 57 Zoraxel 57 EndoTAG TM -1 57 EchoCRT 57 evaluating mipomersen 57 CHARISMA trial 57 DermaVir Patch 57 Prosaptide 57 PROLARIS 57 BARACLUDE R 57 aclidinium 57 Hepatitis C HCV 57 genomic biomarker 57 alemtuzumab MS 57 docetaxel Taxotere R 57 pomalidomide 57 oral rivaroxaban 57 Xcytrin R 57 Trastuzumab DM1 57 SPIRIT III 57 NV1FGF 57 NEUVENGE 57 Onco TCS 57 Clonicel 57 INTERCEPT platelets 57 Diabetic Macular Edema 57 XL# XL# XL# 57 LEVADEX ™ 57 TAXUS V 57 Delcath Phase III 57 oral picoplatin 57 davunetide intranasal AL 57 YONDELIS R 57 PRESEPT study 57 Phase IIa 57 Nasdaq HALO 57 multicenter prospective 57 proteasome inhibitor 57 varespladib 57 dirucotide 57 brivanib 57 EGEN 57 Curaxin CBLC# 57 ALGRX 57 human IgG1 monoclonal 57 Dataflow Manager 57 PENNVAX B 57 COSTAR II 57 TELCYTA 57 cystinosis patients 57 BEMA TM LA 57 afamelanotide 57 evaluating Prochymal 57 ACCLAIM II 57 targeted radiotherapeutic 57 plasma kallikrein inhibitor 57 eprotirome 57 Eliquis 57 JZP 57 Phase III multicenter 57 sipuleucel T 57 clinical trial 57 Serada 57 briakinumab 57 zotarolimus 57 Panzem 57 Hedgehog inhibitor 57 EXPAREL ™ 57 APTIMA HPV 57 oxymorphone ER 57 LAF# 57 Personalized Immunotherapy 56 Quinamed 56 AACR NCI EORTC 56 OMS# 56 KNS # 56 Endeavor drug eluting 56 telomerase therapeutic 56 ALN PCS 56 EndoTAG 56 Pre RELAX AHF 56 Elocalcitol 56 Cloretazine 56 sodium thiosulfate STS 56 Omacetaxine 56 CCR5 mAb 56 orally administered inhibitor 56 Omigard 56 Glybera R 56 Iluvien ® 56 Initiates Phase III 56 satraplatin Phase 56 GRAVITAS trial 56 Fludara ® 56 vitro dissolution 56 Pivotal Phase 56 novel oral anticoagulant 56 Enhanze Technology 56 CLARITY TIMI 56 ITAX 56 Medidur TM FA 56 OLYMPIA registry 56 intranasal delivery 56 E2F Decoy 56 ORMD 56 intranasal formulation 56 ELIQUIS 56 GVAX R 56 blinded randomized placebo controlled 56 pertuzumab 56 CoFactor 56 MYDICAR 56 Oral NKTR 56 CURE AF 56 Locteron ® 56 PF # [002] 56 oral JAK1 56 LHRH receptor positive 56 Nasdaq PGNX today 56 QLT# 56 Acapodene 56 double blinded placebo 56 Phase III Psoriasis 56 Cimzia ® certolizumab pegol 56 Aryplase 56 verteporfin 56 vernakalant hydrochloride 56 nanopharmaceutical 56 Archexin 56 AFRS TM 56 TPI ASM8 56 cellulose sulphate 56 CINTREDEKIN BESUDOTOX 56 systemic RNAi therapeutic 56 TASKi3 56 Vicriviroc 56 Carfilzomib 56 PROSTVAC ® 56 Canvaxin 56 bioequivalency studies 56 Prodarsan ® 56 ZYBRESTAT fosbretabulin 56 lucinactant 56 rPA anthrax vaccine 56 Tesmilifene 56 Survivin antagonist 56 molecular imaging radiopharmaceuticals 56 LBH# 56 factor Xa inhibitor 56 Prodarsan R 56 MIRCERA 56 isavuconazole 56 MLN# 56 Xcellerated T Cells 56 axitinib 56 TMC# [002] 56 TRITON TIMI 56 ProLindac 56 Nasdaq NPSP announced 56 RSD# 56 trodusquemine 56 prospective randomized multicenter 56 SNT MC# 56 cMET 56 Adentri 56 Pemetrexed 56 tremelimumab 56 P2V TM 56 Rhucin ® 56 oral salmon calcitonin 56 Radient Pharmaceutical current 56 Velcade bortezomib 56 HORIZONS AMI trial 56 entinostat 56 diabetic neuropathic pain 56 randomized discontinuation trial 56 specified primary endpoint 56 TELINTRA R 56 small molecule tyrosine 56 luliconazole 56 Zavesca r 56 MedPulser 56 non nucleoside HCV 56 drug GAP #B# 56 PDE# inhibitors 56 PreGen Plus 56 Ozarelix 56 Phase IIa clinical trials 56 Ketotransdel 56 Daclizumab 56 OnDose 56 relapsed MM 56 Edge STudy 56 CIMZIA TM certolizumab pegol 56 Breast Cancer Symposium SABCS 56 FOLFOX6 chemotherapy regimen 56 rEV# 56 XL# SAR# 56 GOUT 56 Oracea TM 56 Provacel 56 ICON7 56 Oral Insulin Capsule 56 #nd EORTC NCI 56 MERLIN TIMI 56 AFREZZA TM 56 GV# [001] 56 tanespimycin 56 INCB# [001] 56 BST CarGel R 56 Ambrisentan 56 Vivecon 56 RE LY 56 torezolid 56 Actimmune ® 56 MAA submission 56 ARISE Phase III 56 TM Drug Eluting 56 subanalysis 56 PEP# [003] 56 Camvia 56 VitiGam 56 pharmacogenomic translational research 56 Breast Cancer Assay 56 BACcel 56 HCD# [002] 56 Hedgehog Pathway Inhibitor 56 QTinno ™ 56 Vidaza ® 56 pharmacodynamic markers 56 INSPIRE Trial Phase III 56 iroxanadine 56 L BLP# 56 nalbuphine ER 56 trials RCTs 56 LEP ETU 56 DCVax R Prostate 56 Serdaxin ® 56 Genta Incorporated OTCBB GETA 56 retinal vein occlusion induced 56 initiate Phase Ib 56 Vernakalant 56 HQK 56 humanised monoclonal antibody 56 Initiates Enrollment 56 DCCR 56 Carotid Revascularization Endarterectomy vs. 56 selective orally bioavailable 56 ACCORD Lipid 56 prospective multicenter randomized 56 Phenoptin 56 VEGF receptor inhibitor 56 CR# vcMMAE 56 PrevOnco ™ 56 rBChE 56 rindopepimut 56 ongoing Phase IIIb 56 Veronate 56 therapeutic monoclonal antibody 56 efficacy endpoint 56 Triapine R 56 aflibercept VEGF Trap 56 product ColonSentry TM 56 IV acetaminophen 56 PNP inhibitor 56 IRX 2 56 Japanese Encephalitis vaccine 56 Glybera 56 postapproval